Details
Stereochemistry | ACHIRAL |
Molecular Formula | C4H9NO2 |
Molecular Weight | 103.1198 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCCC(O)=O
InChI
InChIKey=BTCSSZJGUNDROE-UHFFFAOYSA-N
InChI=1S/C4H9NO2/c5-3-1-2-4(6)7/h1-3,5H2,(H,6,7)
γ-aminobutyric acid (GABA), a naturally occurring substance, which is a product of decarboxylation of the amino acid glutamate mediated by the synthesizing enzyme glutamic acid decarboxylase. GABA is a major inhibitory neurotransmitter of the brain and acts mainly through the GABAA receptor (GABAAR). GABA is locally produced by the pancreatic beta cells. GABAARs are also expressed in various immune cells, including T-cells, peripheral blood mononuclear cells, and are known to exert immune-inhibitory effects. Recently was studied, that GABA has the potential in treatment of Type I Diabetes. Moreover, was shown, that GABA administration could enhance immunity under stress conditions.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14794689
Curator's Comment: -Aminobutyric acid (GABA) was initially identified as a major inhibitory neurotransmitter in the brain by Roberts and Frankel in 1950
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 |
200.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16971751 |
Primary | Unknown Approved UseUnknown |
||
Preventing | THERAPENTIN-90 Approved UseGabapentin Capsules is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. Gabapentin Capsules is also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3 – 12 years. Launch Date2011 |
|||
Sources: http://en.remedy-info.com/gammalon.html https://www.aesthetic-essentials.com/product-page/gammalon-250-mg-100-tablets-gamalon-gamallon-gammaaminoacid https://www.mimaki-family-japan.com/item/detail?item_prefix=TF&item_code=003115&item_branch=001 https://www.ncbi.nlm.nih.gov/pubmed/969409 |
Primary | Gammalon Approved UseGamma-aminobutyric acid helps to restore the metabolism of the brain: activates energy processes, improves glucose utilization and blood supply, increases the respiratory activity of tissues. GABA has a mild psychostimulant effect, has anticonvulsant activity, stabilizes high blood pressure, improves memory, increases the productivity of thinking, helps restore speech and movements after disorders of cerebral circulation.
Given these properties of the active substance, Gammalon is prescribed for adult patients with:
Vascular diseases of the brain (damage of cerebral vessels, atherosclerosis, caused by hypertension), especially in cases when they are accompanied by sleep disorders, headache, dizziness;
Atherosclerosis of cerebral arteries with concomitant phenomena of softening of the brain;
Conditions after cerebrovascular accident, stroke, traumatic brain injury;
Chronic cerebrovascular insufficiency, dyscirculatory encephalopathy, characterized by impaired attention, memory and speech, headaches and dizziness;
Symptom complex of motion sickness (sea, air sickness);
Alcohol encephalopathy;
Alcoholic polyneuritis.
In pediatrics, Gammalon, according to the instructions, is used for:
Cerebral palsy;
Lag of mental development, accompanied by reduced mental activity;
Consequences of birth and / or craniocerebral trauma;
Symptom complex of motion sickness. |
||
Sources: http://en.remedy-info.com/gammalon.html https://www.aesthetic-essentials.com/product-page/gammalon-250-mg-100-tablets-gamalon-gamallon-gammaaminoacid https://www.mimaki-family-japan.com/item/detail?item_prefix=TF&item_code=003115&item_branch=001 https://www.ncbi.nlm.nih.gov/pubmed/969409 |
Primary | Gammalon Approved UseGamma-aminobutyric acid helps to restore the metabolism of the brain: activates energy processes, improves glucose utilization and blood supply, increases the respiratory activity of tissues. GABA has a mild psychostimulant effect, has anticonvulsant activity, stabilizes high blood pressure, improves memory, increases the productivity of thinking, helps restore speech and movements after disorders of cerebral circulation.
Given these properties of the active substance, Gammalon is prescribed for adult patients with:
Vascular diseases of the brain (damage of cerebral vessels, atherosclerosis, caused by hypertension), especially in cases when they are accompanied by sleep disorders, headache, dizziness;
Atherosclerosis of cerebral arteries with concomitant phenomena of softening of the brain;
Conditions after cerebrovascular accident, stroke, traumatic brain injury;
Chronic cerebrovascular insufficiency, dyscirculatory encephalopathy, characterized by impaired attention, memory and speech, headaches and dizziness;
Symptom complex of motion sickness (sea, air sickness);
Alcohol encephalopathy;
Alcoholic polyneuritis.
In pediatrics, Gammalon, according to the instructions, is used for:
Cerebral palsy;
Lag of mental development, accompanied by reduced mental activity;
Consequences of birth and / or craniocerebral trauma;
Symptom complex of motion sickness. |
||
Sources: http://en.remedy-info.com/gammalon.html https://www.aesthetic-essentials.com/product-page/gammalon-250-mg-100-tablets-gamalon-gamallon-gammaaminoacid https://www.mimaki-family-japan.com/item/detail?item_prefix=TF&item_code=003115&item_branch=001 https://www.ncbi.nlm.nih.gov/pubmed/969409 |
Primary | Gammalon Approved UseGamma-aminobutyric acid helps to restore the metabolism of the brain: activates energy processes, improves glucose utilization and blood supply, increases the respiratory activity of tissues. GABA has a mild psychostimulant effect, has anticonvulsant activity, stabilizes high blood pressure, improves memory, increases the productivity of thinking, helps restore speech and movements after disorders of cerebral circulation.
Given these properties of the active substance, Gammalon is prescribed for adult patients with:
Vascular diseases of the brain (damage of cerebral vessels, atherosclerosis, caused by hypertension), especially in cases when they are accompanied by sleep disorders, headache, dizziness;
Atherosclerosis of cerebral arteries with concomitant phenomena of softening of the brain;
Conditions after cerebrovascular accident, stroke, traumatic brain injury;
Chronic cerebrovascular insufficiency, dyscirculatory encephalopathy, characterized by impaired attention, memory and speech, headaches and dizziness;
Symptom complex of motion sickness (sea, air sickness);
Alcohol encephalopathy;
Alcoholic polyneuritis.
In pediatrics, Gammalon, according to the instructions, is used for:
Cerebral palsy;
Lag of mental development, accompanied by reduced mental activity;
Consequences of birth and / or craniocerebral trauma;
Symptom complex of motion sickness. |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02002130
Patients will receive the Active GABA (Gamma-Amino Butyric Acid) capsules. Each capsule 250mg. Dosage will be calculated according to body surface area of the child and divided between 2 meals/day. Larger dose taken with larger meal.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17942900
The HEK293 cells constitutively expressing exogenous GABA receptor π subunit (GABRP) revealed the growth-promoting effect of GABA treatment (serial concentrations: 0, 1, 10, 100 μmol/L);for 6 d). GABA treatment stimulated GABRP-positive pancreatic ductal adenocarcinoma (PDAC) cell proliferatio and activated the mitogen-activated protein kinase/extracellular signal–regulated kinase (MAPK/Erk) cascade. These findings imply that GABA and GABRP could play important roles in PDAC development and progression, and that this pathway can be a promising molecular target for the development of new therapeutic strategies for PDAC.
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
443 (Number of products:610)
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
||
|
WHO-VATC |
QN03AG03
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
||
|
WHO-ATC |
N03AG03
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
||
|
EPA PESTICIDE CODE |
30802
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
||
|
JECFA EVALUATION |
4-AMINOBUTYRIC ACID
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
||
|
NCI_THESAURUS |
C687
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
257
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
GAMMA-AMINOBUTYRIC ACID
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
200-258-6
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
100000078174
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
595
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
D005680
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
1020023
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
618771
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
ALTERNATIVE | |||
|
70582
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
ALTERNATIVE | |||
|
DTXSID6035106
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
4617
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
C80523
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
2ACZ6IPC6I
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
27418
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
618257
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
ALTERNATIVE | |||
|
16865
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
2ACZ6IPC6I
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
1749
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
m1695
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | Merck Index | ||
|
1262
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
SUB127282
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
CHEMBL96
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
DB02530
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
119
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
56-12-2
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY | |||
|
SUB13946MIG
Created by
admin on Fri Dec 15 15:13:21 GMT 2023 , Edited by admin on Fri Dec 15 15:13:21 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)